Prostate cancer is the most common neoplasm in men and its management is very complex, in terms of both diagnosis and treatment. In recent years the value of multidisciplinary management within a prostate cancer unit has been increasingly recognized. Such a multidisciplinary approach within a specialized unit involves a variety of specialists, including urologists, oncologists, radiotherapists, radiologists and pathologists. This book describes in detail the advantages of multidisciplinary management of prostate cancer. It opens by explaining the nature of the required multidisciplinary team and the potential benefits of the prostate cancer unit as a structure for the delivery of specialist multidisciplinary care. Epidemiological aspects favoring multidisciplinary management are described and each element of care within the context of the prostate cancer unit is then discussed; also has been described the role of advanced imaging (Multiparametric MRI) in the management of PCa. Early diagnosis, risk classification, treatment decision making, surgery, radiotherapy, medical therapies and health care support are all fully considered. This book will be informative and enlightening for all who are involved in the management of patients with prostate cancer.
विषयसूची
Multidisciplinary team (MDT) in cancer management.- Prostate cancer units: how and why.- Comparison between a multidisciplinary and a mono disciplinary approach to prostate cancer: our experience.- Pathology and clinic.- The dilemma of early diagnosis for a clinically relevant prostate cancer: the role of the urologist in a MDT.- Modern imaging in the initial diagnosis: the role of the radiologist in a MDT.- How to define the primary treatment : the role of the urologist and the radiotherapist in a MDT.- Early diagnosis of failure after primary treatment: multiparametric MRI versus PET-CT.- Intermittent androgen deprivation in the new era: the role of the urologist and the oncologist in a MDT.- New medical strategies: the role of the oncologist in a MDT.- Focal therapies: MRg FUS our experience.